Antibody-drug conjugates (ADCs) have demonstrated their effectiveness in a variety of solid tumors such as breast, lung, ovarian or bladder cancer and in hematological cancers too. However, in some cancer types, like pancreatic cancer, treatment with ADCs needs enhancement through more appropriate targets and payloads.
Bioversys AG has announced that its BV500 NTM program has reached its second milestone with the identification of up to five optimized lead compounds, under the CF AMR Syndicate collaborative discovery program agreement.
High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited availability of effective targeted therapies for platinum-resistant HGSC presents a significant clinical challenge.
Researchers in from Nanjing Drum Tower Hospital have presented data from a study that investigated the role of immunoglobulin superfamily member 6 (IGSF6) microglia during ischemic stroke.
Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.
Voyager Therapeutics Inc. has announced its decision to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Emerging preclinical data indicate the siRNA payload component of VY-9323 does not meet its standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Bind Research has launched as a not-for-profit focused research organization (FRO) with the aim of transforming disordered proteins into viable drug targets. The organization has secured financing from the U.K. Government’s Research Venture Catalyst program, with matched support from industry, philanthropic and charitable donors.
RSS
